EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction

Maxwell Quinn, Richard Y K Zhang iD, Idris Bello, Kerry-Anne Rye iD, Shane R Thomas

Antioxidants · 28.06.2024 · 13 (7) · 788

DOI: 10.3390/antiox13070788 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Antioxidants, online erschienen am 28.06.2024. Verfasst von Maxwell Quinn und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cardiometabolic Disease Research Group, School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW 2052,…. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 233 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Medical Research Future Fund, National Health and Medical Research Council, Heart Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coronary artery disease (CAD) and myocardial infarction (MI) remain leading causes of death and disability worldwide. CAD begins with the formation of atherosclerotic plaques within the intimal layer of the coronary arteries, a process driven by persistent arterial inflammation and oxidation. Myeloperoxidase (MPO), a mammalian haem peroxidase enzyme primarily expressed within neutrophils and monocytes, has been increasingly recognised as a key pro-inflammatory and oxidative enzyme promoting the development of vulnerable coronary atherosclerotic plaques that are prone to rupture, and can precipitate a MI. Mounting evidence also implicates a pathogenic role for MPO in the inflammatory process that follows a MI, which is characterised by the rapid infiltration of activated neutrophils into the damaged myocardium and the release of MPO. Excessive and persistent cardiac inflammation impairs normal cardiac healing post-MI, resulting in adverse cardiac outcomes and poorer long-term cardiac function, and eventually heart failure. This review summarises the evidence for MPO as a significant oxidative enzyme contributing to the inappropriate inflammatory responses driving the progression of CAD and poor cardiac healing after a MI. It also details the proposed mechanisms underlying MPO’s pathogenic actions and explores MPO as a novel therapeutic target for the treatment of unstable CAD and cardiac damage post-MI.

Schlagwörter

Stichwörter der Autor:innen

atherosclerosisheart failureleft ventricular remodellingmyeloperoxidasemyocardial infarctionoxidative stress

Autor:innen und Institutionen

  • Cardiometabolic Disease Research Group, School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW 2052, Australia.

ORCID-Profile: Richard Y K Zhang, Kerry-Anne Rye

Förderung

  • Australian Medical Research Future Fund
  • National Health and Medical Research Council
  • Heart Foundation

Zitieren

APA

Quinn, M., Zhang, R. Y. K., Bello, I., Rye, K. A., & Thomas, S. R. (2024). Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction. Antioxidants, 13(7), 788. https://doi.org/10.3390/antiox13070788

Vancouver

Quinn M, Zhang RYK, Bello I, Rye KA, Thomas SR. Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction. Antioxidants. 2024;13(7):788. doi:10.3390/antiox13070788

BibTeX
@article{Quinn2024,
  author = {Quinn, Maxwell and Zhang, Richard Y K and Bello, Idris and Rye, Kerry-Anne and Thomas, Shane R},
  title = {Myeloperoxidase as a Promising Therapeutic Target after Myocardial Infarction},
  journal = {Antioxidants},
  year = {2024},
  volume = {13},
  number = {7},
  pages = {788},
  doi = {10.3390/antiox13070788}
}
Kostenlos starten →